Nature Reviews Clinical Oncology - Table of Contents Volume 6 Issue 9
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Yohann Loriot1, Pierre Mordant2, Eric Deutsch2, Ken André Olaussen3 & Jean-Charles Soria1 About the authors
KRAS mutations may be predictive of resistance to anti-EGFR monoclonal-based therapy in patients with colorectal cancer (CRC). Screening for KRAS mutations in patients with CRC and non-small-cell lung cancer (NSCLC) may provide additional information on optimizing treatment options with targeted therapies. Only limited studies, however, have assessed the predictive value of KRAS mutations in response to conventional chemotherapy. We reviewed all relevant papers investigating the association of KRAS mutations and conventional chemotherapy-related outcome in NSCLC, CRC, and other solid tumors, both in the adjuvant and advanced settings. Our Review strongly suggests that KRAS mutations have no value in response prediction to conventional chemotherapy in NSCLC, CRC and other solid tumors. Therefore, KRAS mutations should not be used as molecular predictors of response to conventional chemotherapy.